Ultima Markets[Market Hotspot] Johnson&Johnson's Q4 performance exceeded expectations,...

Johnson&Johnson (JNJ.US) The fourth quarter performance exceeded analyst expectations. The company's announcement2023The sales revenue in the fourth quarter of the year is214Billion US dollars, with a net income of41.3 USD100mn Earnings per share (EPS) by1.70 USD, while the earnings per share for the same period last year were1.22 In US dollars, the net income at that time was32.3 USD100mn Excluding one-time items, the company's adjusted earnings per share for the most recent quarter are 2.29 USD.

Split consumer health company under Yu's umbrella Kenvue Later, Johnson&Johnson now operates through two business departments: Innovation Medicine (composed of its pharmaceutical division) and Medical Technology (Medical Equipment Division). Innovation Medicine Revenue Growth This Season 4.2%, reaching 137 Billion US dollars, while medical technology sales soar13.3%, reaching 77 USD100mn

Johnson&Johnson has made progress in obtaining approval for a variety of new therapies, including Balversa Medications. However, the company's lucrativeStelara The drug will be delivered as soon as possible 2024 Facing increasingly fierce competition in Europe in the middle of the year. During an investor conference call, CEO Huajin Duato(Joaquin Duato) Johnson&Johnson is seeking more acquisition cases and is willing to consider "various types of transactions.".

Johnson&Johnson 2024 Annual Prospective Guidelines and 12 The monthly forecast is consistent. The company expects its operating sales to grow5-6%, reaching 882100 million US dollars to890USD100mn For profitability, Johnson&Johnson expects adjusted earnings per share to be 10.55-10.75 USD, increased compared to last year6.4-8.4%。 This EPS Guidelines and Wall Street expectations 10.68The US dollars are the same.

(Johnson&Johnson stock price monthly chart)

Disclaimers

The comments, news, research, analysis, pricing, and other information contained in this article can only be considered as general market information and are provided solely to assist readers in understanding the market situation and do not constitute investment advice.Ultima MarketsReasonable measures have been taken to ensure the accuracy of the data, but the accuracy of the data cannot be guaranteed and can be changed at any time without notice.Ultima MarketsWe will not be responsible for any losses or losses (including but not limited to any loss of profits) that may arise from the direct or indirect use or reliance on such information.